Non-formulary insulin degludec (Tresiba®) will be covered on the prescription drug benefit when the following criteria are met:

- Must show documented intolerance to insulin glargine

-AND-

- Use in patients with type 1 diabetes mellitus as basal insulin

-OR-

- Use in patients with type 2 diabetes mellitus that experience recurrent nocturnal hypoglycemia with bedtime NPH dosing defined as: 3 or more episodes of nocturnal CBG less than 70 over the preceding 30 days that persists despite NPH dose reduction

  **For patients on 70/30, trial of NPH (dosed am and bedtime) and R (dosed breakfast and dinner) insulin where the bedtime dose of NPH resulted in recurrent hypoglycemia as defined above

-OR-

- Use in patients with type 2 diabetes mellitus on NPH that experience any episode of severe hypoglycemia defined as: hypoglycemia resulting in seizures, loss of consciousness, episode necessitating assistance from someone else, EMT, use of glucagon

-OR-

- Use in patient with type 2 diabetes mellitus that require ultra-long acting insulin due to work (night shift work where hours of sleep are significantly and repeatedly varied over time, frequent time-zone traveler)

-OR-

- Dose Change Only: Patient meets current criteria and is already taking the drug.